In my opinion, Biden is President is also good news for dealing competently with the pandemic in the United States.
-
-
- End of conversation
New conversation -
-
-
Any thoughts on using prophylactic monoclonal antibodies in the immune deficient population, similar to how we receive immune globulins today. This would only be needed until antibodies are in the plasma supply.
-
Wouldn’t we need more supply now than they’ve been able to produce? We don’t have enough supply to use this treatment on everyone who is sick
- Show replies
New conversation -
-
-
Israel hasn't and won't show anything about efficient virus containment. A month into lockdown and with 50%+ vaccinated, deaths are at all time high. Not to mention economic collapse.https://mobile.twitter.com/VasiliyZukanov/status/1353096104875847685 …
-
You do know there is a lag in deaths of like a month in most cases, right?
- Show replies
New conversation -
-
-
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percenthttps://investor.lilly.com/news-releases/news-release-details/new-data-show-treatment-lillys-neutralizing-antibodies …
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Can you clarify how anything relating to monoclonal antibodies is good when they’re not widely available and very expensive?
-
That this is the first evidence of anything working, reduction and distribution will be a nightmare but it’s still good news
End of conversation
New conversation -
-
-
Are we still not vaccinating enough? Still think Biden needs new ideas to get it going faster.
-
He’s got ideas, needs a little time to get them implemented. Supplies to the states are increasing starting next week.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
1. Pivotal trial of early monoclonal antibodies reduces death & hospitalization (big, this is a 1st)
2. Vaccination & mitigation works to contain B.1.1.7 (as shown by Israel)
3. The other 501Y.V2/3 variants are unlikely to reduce vaccine efficacy